I lead Research and Development in Oncology at AstraZeneca and am responsible for discovery through late-stage development of large and small molecules.

Prior to my role at AstraZeneca, I served as the Physician-in-Chief and Chief Medical Officer at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weill Cornell Medical College. In this capacity, I had nearly 2,000 physicians reporting to me and under my leadership, MSK became the leader in early phase clinical trials for cancer therapies and diagnostic genetic sequencing.

My long-standing research interests are in the development of targeted agents for the treatment of cancer and in studying strategies to overcome mechanisms of resistance. My passion for drug development has also led to the creation of a number biopharmaceutical companies.

Prior to joining MSKCC, I was Chief of the Division of Hematology/Oncology and Associate Director at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. I was also the Chairman of Medical Oncology and Founding Director of the Vall d ‘Hebron Institute of Oncology in Barcelona, Spain.

The possibilities of scientific discovery are endless, but it is up to us as researchers and innovators to bring them forward to improve the lives of patients.

José Baselga Executive Vice-President, Research & Development Oncology


Lifetime Achievement Award, European Society for Medical Oncology


Mike Price Gold Medal Award, The European Association for Cancer Research


Rosenthal Family Foundation Award American Association for Cancer Research (AACR)

Key Achievements

Chief Scientist


Appointed Executive Vice-President, Research & Development Oncology, AstraZeneca

2000 - 2015

Pivotal laboratory and clinical studies led to the approval of cetuximab, trastuzumab, pertuzumab and everolimus, among other oncology therapies


Assumed term as President, American Association for Cancer Research (AACR) Academy

  Featured publications

Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer.

Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. N Engl J Med. 2012; 366:520-9.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

von Minckwitz G*, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J*; APHINITY Steering Committee and Investigators. N Engl J Med. 2017 Jun 5; 377:122-131.  PMCID:PMC5538020.  *Co-corresponding authors. 

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. J Clin Oncol. 2018 May 1;36(13):1291-1299.

Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor.

Juric D, Castel P, Griffit M, Griffith OL, Won HH, Ellis H, Ebbesen S, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J*, Scaltriti M. Nature. 2015 Feb 12; 518(7538):240-4

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.

Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J.
Science. 2017 Mar 24;355(6331):1324-1330.

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS & Baselga J (2018). Cancer Cell 34, 427-438 e426.